Show all

Q2 2027 Report

Helus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business Highlights

- Appointed Michael Halstead as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization -

- Completed enrollment in the Phase 3 APPROACH pivotal study of HLP003 in major depressive disorder (“MDD”); topline data remains on track for Q4 20261,2-

- Announced design of upcoming HLP004 Phase 2 monotherapy study in generalized anxiety disorder (“GAD”); expected to initiate in Q1 20271,2  -

- Appointed Dr. Suresh Durgam, former Executive Vice President and Chief Medical Officer of Intra-Cellular Therapies, Inc. to the Company’s Board of Directors -

- Appointed Helus Pharma board member, Mark Lawson, independent Chair of the Board of Directors  -

View full release

Q1 2027 Report

Helus Pharma Reports First Quarter Fiscal Year 2027 Financial Results

- Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization -

- Completed enrollment in the Phase 3 APPROACH pivotal study of HLP003 in Major Depressive Disorder (“MDD”); topline data remain on track for Q4 20261,2 -

- Completed Drug-Drug Interaction (“DDI”) study demonstrated a favorable DDI profile supporting HLP003 as an adjunctive treatment for MDD -

- Continued enrollment in EMBRACE, the second pivotal study in the Phase 3 PARADIGM program -

- Continued participant rollover into EXTEND to generate long-term safety and durability data -

View full release

Q2 2026 Report

Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights

- Closed registered direct offering for aggregate gross proceeds of US$175 million (the “Registered Direct Offering”) led by a syndicate of prominent biopharmaceutical institutional investors -

- On track to report topline data from Phase 2 study evaluating CYB004 for the treatment of Generalized Anxiety Disorder (“GAD”) in Q1 20261 -

- Continues to advance Phase 3 studies of CYB003 for the adjunctive treatment of major depressive disorder (“MDD”) -

View full release

Q1 2026 Report

Cybin Reports Important Progress on Key Milestones and First Quarter Fiscal Year 2026 Financial Results

Cybin continues to make significant progress on its journey to bring breakthrough therapies to patients by delivering on the following key milestones

- Received European and United Kingdom Medical and Healthcare Products Regulatory Agency (“MHRA”) approval for EMBRACE, the Company’s second pivotal study evaluating CYB003 for the adjunctive treatment of Major Depressive Disorder (“MDD”) on schedule -

- EMBRACE study to enroll 330 participants at approximately 60 clinical sites across the United States, United Kingdom, Europe, and Australia1 -

View full release